In this issue:
Risk of all-cause, sudden death, and cardiovascular mortality among antipsychotic-treated patients with schizophrenia
Transitioning from once-monthly to once-every- 3-months paliperidone palmitate for schizophrenia
Treatment goals in schizophrenia: A real-world survey
Global fractional anisotropy predicts transition to psychosis in individuals at ultra-high risk for psychosis
SLE and autoimmune features in chronic schizophrenia patients
Association of medical resource utilisation with physical morbidity and premature mortality in schizophrenia
Risk factors, incidence, and outcomes of NMS on LAI vs oral antipsychotics in schizophrenia
Long-term continuity of antipsychotic treatment for schizophrenia
Improving social functioning in SSD via mobile experimental interventions
Clozapine-induced myocarditis and outcomes after drug rechallenge following myocarditis
Please login below to download this issue (PDF)